Autoantibodies Produced at the Site of Tissue Damage Provide Evidence of Humoral Autoimmunity in Inclusion Body Myositis

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Ray, Arundhati ^a   Amato, Anthony A ^b   Bradshaw, Elizabeth M ^c   Felice, Kevin J ^d,e   DiCapua, Daniel B ^a   Goldstein, Jonathan M ^a   Lundberg, Ingrid E ^f   Nowak, Richard J ^a   Ploegh, Hidde L ^g   Spooner, Eric ^g   Wu, Qian ^h   Willis, Simon N ^a,i   O'Connor, Kevin C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Hospital for Special Care New Britain   (United States)

^e UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^h UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

ⁱ WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DESMIN; IMMUNOGLOBULIN; RECOMBINANT IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; CELL ISOLATION; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOREACTIVITY; INCLUSION BODY MYOSITIS; MASS SPECTROMETRY; MUSCLE TISSUE; PLASMA CELL; PROTEIN EXPRESSION; TISSUE INJURY;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; CASE-CONTROL STUDIES; CELL LINE; DESMIN; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MICE; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; PROTEIN BINDING;

EID: 84867179869     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046709     Document Type: Article

References (34)

1. Dalakas MC, Sivakumar K, (1996) The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Curr Opin Neurol 9: 235-239.
2. Greenberg SA, (2010) Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 12: 221-228.
3. Hohlfeld R, (2011) Update on sporadic inclusion body myositis. Brain 134: 3141-3145.
4. Needham M, Mastaglia FL, (2007) Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 6: 620-631.
5. Zong M, Lundberg IE, (2011) Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 7: 297-306.
6. Askanas V, Engel WK, (2007) Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 19: 550-559.
7. Salajegheh M, Pinkus JL, Amato AA, Morehouse C, Jallal B, et al. (2010) Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 42: 576-583.
8. Dalakas MC, (2006) Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 66: S33-38.
9. Hohlfeld R, Dornmair K, (2007) Revisiting the immunopathogenesis of the inflammatory myopathies. Neurology 69: 1966-1967.
10. Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, et al. (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 50: 2206-2213.
11. Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, et al. (2005) Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65: 1782-1787.
12. Bradshaw EM, Orihuela A, McArdel SL, Salajegheh M, Amato AA, et al. (2007) A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 178: 547-556.
13. Dalakas MC, Illa I, Gallardo E, Juarez C, (1997) Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol 41: 100-104.
14. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, et al. (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60: 116-123.
15. Salajegheh M, Lam T, Greenberg SA, (2011) Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 6: e20266.
16. Krystufkova O, Vallerskog T, Helmers SB, Mann H, Putova I, et al. (2009) Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 68: 836-843.
17. Senecal JL, Rauch J, (1988) Hybridoma lupus autoantibodies can bind major cytoskeletal filaments in the absence of DNA-binding activity. Arthritis Rheum 31: 864-875.
18. Menge T, Rzepka R, Melchers I, (2002) Monoclonal autoantibodies from patients with autoimmune diseases: specificity, affinity and crossreactivity of MAbs binding to cytoskeletal and nucleolar epitopes, cartilage antigens and mycobacterial heat-shock protein 60. Immunobiology 205: 1-16.
19. Varon D, Linder S, Gembom E, Guedg L, Langbeheim H, et al. (1990) Human monoclonal antibody derived from an autoimmune thrombocytopenic purpura patient, recognizing an intermediate filament's determinant common to vimentin and desmin. Clin Immunol Immunopathol 54: 454-468.
20. Post GR, Dawson G, (1992) Characterization of a cell line derived from a human oligodendroglioma. Mol Chem Neuropathol 16: 303-317.
21. Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, et al. (2009) The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. J Immunol 182: 3310-3317.
22. Wang X, Stollar BD, (2000) Human immunoglobulin variable region gene analysis by single cell RT-PCR. J Immunol Methods 244: 217-225.
23. Owens GP, Bennett JL, Lassmann H, O'Connor KC, Ritchie AM, et al. (2009) Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 65: 639-649.
24. O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, et al. (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13: 211-217.
25. Dimitri D, Benveniste O, Dubourg O, Maisonobe T, Eymard B, et al. (2006) Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain 129: 986-995.
26. Fyhr IM, Moslemi AR, Lindberg C, Oldfors A, (1998) T cell receptor beta-chain repertoire in inclusion body myositis. J Neuroimmunol 91: 129-134.
27. Amemiya K, Granger RP, Dalakas MC, (2000) Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123 (Pt 10): 2030-2039.
28. Bender A, Behrens L, Engel AG, Hohlfeld R, (1998) T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 84: 86-91.
29. Duskin A, Eisenberg RA, (2010) The role of antibodies in inflammatory arthritis. Immunol Rev 233: 112-125.
30. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112.
31. Gunawardena H, Betteridge ZE, McHugh NJ, (2008) Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 20: 675-680.
32. Koffman BM, Rugiero M, Dalakas MC, (1998) Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 21: 115-117.
33. Selva-O'Callaghan A, Mijares-Boeckh-Behrens T, Labrador-Horrillos M, Solans-Laque R, Ma Grau-Junyent J, et al. (2003) Anti-PM-Scl antibodies in a patient with inclusion body myositis. Rheumatology (Oxford) 42: 1016-1018.
34. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, et al. (2008) Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 131: 1228-1240.